CVM Pengajuan SEC - CEL-SCI Corporation- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	549300FIWOFSETIVMI17
CIK	725363

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CEL-SCI Corporation

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 29, 2025	EX-99.2	CEL-SCI ANNOUNCES CLOSING OF $10 MILLION PUBLIC OFFERING EXHIBIT 99.2 NEWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF $10 MILLION PUBLIC OFFERING Vienna, Virginia – August 29, 2025 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company,
August 29, 2025	EX-99	CEL-SCI CORPORATION Common Stock EXHIBIT 99 CEL-SCI CORPORATION Common Stock This Prospectus relates to shares (the "Shares") of common stock (the "Common Stock") of CEL-SCI Corporation which may be issued pursuant to certain employee compensation plans adopted by CEL-SCI.
August 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 27, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 27, 2025 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission Fil
August 29, 2025	EX-99.1	CEL-SCI ANNOUNCES PRICING OF $10 MILLION PUBLIC OFFERING EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $10 MILLION PUBLIC OFFERING Vienna, Virginia – August 27, 2025 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company,
August 29, 2025	EX-4.(C)	CEL-SCI CORPORATION 2025 STOCK BONUS PLAN EXHIBIT 4(c) CEL-SCI CORPORATION 2025 STOCK BONUS PLAN l. Purpose. The purpose of this Stock Bonus Plan is to advance the interests of CEL-SCI Corporation (the “Company”) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for the successful conduct of its business,
August 29, 2025	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities EXHIBIT 107 Calculation of Filing Fee Tables S-8 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock, Preferred Stock, Rights and Warrants Rule 457(o) 133,334 $ 13.
August 29, 2025	S-8	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of l933 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of l933 CEL-SCI CORPORATION (Exact name of issuer as specified in its charter) Colorado 84-0916344 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8229 Boone Blvd., Suite 802 Vienna, Virginia 22182 (Address of Principal Executive Off
August 29, 2025	EX-1.1	PLACEMENT AGENCY AGREEMENT CEL-SCI CORPORATION THINKEQUITY LLC EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC 1 CEL-SCI CORPORATION PLACEMENT AGENCY AGREEMENT New York, New York August 27, 2025 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 Ladies and Gentlemen: This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC ("ThinkEquity" or the "Placement Agent") shall
August 29, 2025	EX-4.(B)	CEL-SCI CORPORATION 2025 NON-QUALIFIED STOCK OPTION PLAN EXHIBIT 4(b) CEL-SCI CORPORATION 2025 NON-QUALIFIED STOCK OPTION PLAN l. Purpose. This Non-Qualified Stock Option Plan (the "Plan") is intended to advance the interests of CEL-SCI Corporation (the “Company”) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for th
August 28, 2025	424B5	Per Share Filed pursuant to Rule 424(b)(5) Registration No. 333-288515 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 12, 2025) 1,111,200 Shares Common Stock CEL-SCI Corporation We are offering 1,111,200 shares of our common stock par value $0.01 per share, pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price of $9.00 per share. We have enga
August 27, 2025	424B5	SUBJECT TO COMPLETION Filed pursuant to Rule 424(b)(5) Registration No. 333-288515 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended. This preliminary prospectus su
August 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 22, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 22, 2025 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission Fil
August 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-11889 CEL-SCI C
August 5, 2025	EX-3.F	Amended Articles (reverse stock split only) EXHIBIT 3(f) CEL-SCI CORPORATION ATTACHMENT TO ARTICLES OF AMENDMENT The following is added to Article 4: Effective May 19, 2025, all outstanding shares of the Company’s common stock were combined on a 30-for-1 basis. Each outstanding share of the Company’s common stock will be combined into one share of common stock.
August 5, 2025	S-3/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-09l6344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including zip code, and te
August 5, 2025	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables S-3 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock, Preferred Stock, Rights and Warrants Rule 457(o) $ 100,000,000 $153.
July 14, 2025	EX-99.2	CEL-SCI ANNOUNCES CLOSING OF $5.7 MILLION OFFERING PRICED AT-THE-MARKET UNDER NYSE AMERICAN RULES EXHIBIT 99.2 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF $5.7 MILLION OFFERING PRICED AT-THE-MARKET UNDER NYSE AMERICAN RULES Vienna, Virginia – July 14, 2025 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinic
July 14, 2025	EX-99.1	CEL-SCI ANNOUNCES PRICING OF $5.7 MILLION OFFERING PRICED AT-THE-MARKET UNDER NYSE AMERICAN RULES EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $5.7 MILLION OFFERING PRICED AT-THE-MARKET UNDER NYSE AMERICAN RULES Vienna, Virginia – July 11, 2025 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinic
July 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 11, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 11, 2025 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File
July 14, 2025	EX-1.1	Placement Agency Agreement dated July 11, 2025, by and between CEL-SCI Corporation and ThinkEquity, LLC EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC 1 CEL-SCI CORPORATION PLACEMENT AGENCY AGREEMENT New York, New York July 11, 2025 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 Ladies and Gentlemen: This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC ("ThinkEquity" or the "Placement Agent") shall b
July 14, 2025	424B5	Per Share Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) 1,500,000 Shares Common Stock CEL-SCI Corporation We are offering 1,500,000 shares of our common stock par value $0.01 per share, pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price of $3.82 per share. We have engage
July 3, 2025	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables S-3 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock, Preferred Stock, Rights and Warrants Rule 457(o) $ 100,000,000 $153.
July 3, 2025	S-3	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 Registration Statement Under THE SECURITIES ACT OF 1933 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-09l6344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including zip code, and telephone number i
July 3, 2025	EX-3.F	Amended Articles (reverse stock split only) EXHIBIT 3(f) CEL-SCI CORPORATION ATTACHMENT TO ARTICLES OF AMENDMENT The following is added to Article 4: Effective May 19, 2025, all outstanding shares of the Company’s common stock were combined on a 30-for-1 basis. Each outstanding share of the Company’s common stock will be combined into one share of common stock.
May 23, 2025	EX-99.1	CEL-SCI ANNOUNCES PRICING OF PUBLIC OFFERING EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF PUBLIC OFFERING Vienna, VA, May 21, 2025 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pr
May 23, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 21, 2025 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File N
May 23, 2025	EX-99.2	CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING EXHIBIT 99.2 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING Vienna, VA, May 23, 2025 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the cl
May 23, 2025	EX-1.1	Underwriting Agreement dated as of May 21, 2025, by and between CEL-SCI Corporation and ThinkEquity, LLC EXHIBIT 1.1 UNDERWRITING AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC as Representative of the Several Underwriters CEL-SCI CORPORATION UNDERWRITING AGREEMENT New York, New York May 21, 2025 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Floor New York, NY 10004 Ladies and Gentlemen: The undersigned, CEL-SCI Corp
May 22, 2025	424B5	Per Share Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) 2,000,000 Shares Common Stock CEL-SCI Corporation We are offering 2,000,000 shares of our common stock par value $0.01 per share, pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price of $2.50 per share. Our common sto
May 21, 2025	424B5	SUBJECT TO COMPLETION Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended. This preliminary prospectus su
May 19, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 19, 2025 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File N
May 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-11889 CEL-SCI
April 9, 2025	ARS	ARS
April 9, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive
March 21, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive
March 18, 2025	EX-1.1	Placement Agency Agreement dated March 17, 2025, by and between CEL-SCI Corporation and ThinkEquity, LLC EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC CEL-SCI CORPORATION PLACEMENT AGENCY AGREEMENT New York, New York March 17, 2025 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 Ladies and Gentlemen: This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC ("ThinkEquity" or the "Placement Agent") shall be
March 18, 2025	EX-99.2	CEL-SCI ANNOUNCES CLOSING OF $2.5 MILLION OFFERING EXHIBIT 99.2 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF $2.5 MILLION OFFERING Vienna, Virginia – March 18, 2025 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing
March 18, 2025	424B5	Per Share Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) 4,012,500 Shares of Common Stock 11,987,500 Pre-Funded Warrants to Purchase Shares of Common Stock CEL-SCI Corporation We are offering 4,012,500 shares of our common stock par value $0.01 per share, pursuant to this prospectus supplement and the accompanying prospectus. The shares
March 18, 2025	EX-4.1	Form of Pre-Funded Warrant EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT CEL-SCI CORPORATION Warrant Shares: 11,987,500 Issue Date: March 18, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, 3i, LP or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t
March 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 17, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 17, 2025 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File
March 18, 2025	EX-99.1	CEL-SCI ANNOUNCES PRICING OF $2.5 MILLION OFFERING EXHIBIT 99.1 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $2.5 MILLION OFFERING Vienna, Virginia – March 17, 2025 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing
March 3, 2025	CORRESP	HART & HART, LLC ATTORNEYS AT LAW 1624 Washington Street Denver, CO 80203 HART & HART, LLC ATTORNEYS AT LAW 1624 Washington Street Denver, CO 80203 (303) 839-0061 harttrinen@aol.
February 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-11889 CEL-S
January 13, 2025	EX-19	Insider Trading Policies and Procedures EXHIBIT 19 CEL-SCI CORPORATION Insider Trading Policy I. PURPOSE CEL-SCI Corporation (the “Company”) has adopted this Insider Trading Policy (this “Policy”) to help its directors and officers comply with insider trading laws, to prevent even the appearance of improper insider trading and to promote compliance with the Company’s obligation under Item 408 of Regulation S-K to publicly disclose infor
January 13, 2025	10-K	FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-11889 CEL-SCI CORPORATION (Exact
January 3, 2025	424B3	CEL-SCI CORPORATION 1,000,000 Shares of Common Stock 424(b)(3) File #333-282844 PROSPECTUS CEL-SCI CORPORATION 1,000,000 Shares of Common Stock This prospectus relates to the possible resale, from time to time, by the selling shareholder identified in this prospectus of up to 1,000,000 shares of our common stock, which were issued in partial payment of amounts owed for services in connection with our confirmatory Phase III clinical trial.
December 31, 2024	EX-4.1	Form of Pre-Funded Warrant EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT CEL-SCI CORPORATION Warrant Shares: Issue Date: December, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and
December 31, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 29, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission F
December 31, 2024	EX-1.1	Placement Agency Agreement dated December 29. 2024, by and between CEL-SCI Corporation and ThinkEquity, LLC EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC CEL-SCI CORPORATION PLACEMENT AGENCY AGREEMENT New York, New York December 29, 2024 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 Ladies and Gentlemen: This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC ("ThinkEquity" or the "Placement Agent") shall
December 31, 2024	EX-99.1	CEL-SCI ANNOUNCES PRICING OF $5 MILLION PUBLIC OFFERING EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $5 MILLION PUBLIC OFFERING Vienna, Virginia – December 29, 2024 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today
December 31, 2024	EX-99.2	CEL-SCI ANNOUNCES CLOSING OF $5 MILLION OFFERING EXHIBIT 99.2 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF $5 MILLION OFFERING Vienna, Virginia – December 31, 2024 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a cancer immunotherapy company, today announced the c
December 30, 2024	424B5	Per Share Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) 7,552,500 Shares of Common Stock 8,577,500 Pre-Funded Warrants to Purchase Shares of Common Stock 8,577,500 Shares of Common Stock Underlying the Pre-Funded Warrants CEL-SCI Corporation We are offering 7,552,500 shares of our common stock par value $0.01 per share, pursuant to thi
December 30, 2024	NT 10-K	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 NT 10-K 1 cvmnt10k.htm NT 10-K U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SEC File Number 001-11889 CUSIP Number 150837508 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR For Period Ended: September 30, 2024. ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q For the Transition Period E
December 27, 2024	424B5	SUBJECT TO COMPLETION Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended. This preliminary prospectus su
November 15, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 13, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission F
November 13, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 12, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission F
November 5, 2024	CORRESP	CEL-SCI CORPORATION 8229 Boone Blvd. #802 Vienna, VA 22182 (703) 506-9460 November 5, 2024 CEL-SCI CORPORATION 8229 Boone Blvd. #802 Vienna, VA 22182 (703) 506-9460 November 5, 2024 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: CEL-SCI Corporation Form S-3 SEC File No. 333-282844 CEL-SCI Corporation (the “Company”) requests that the effective date of the above captioned Registration Statement be accelerated to Thursday, November 7, 2024 at 4:00 P.M. Easter
October 30, 2024	S-3/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including zip code, and te
October 30, 2024	EX-4	Securities Purchase Agreement between CEL-SCI Corporation and Ergomed Group Limited, dated October 18, 2024 EXHIBIT 4 SECURITIES PURCHASE AGREEMENT between CEL-SCI CORPORATION and ERGOMED GROUP LIMITED dated as of October 18, 2024 1 TABLE OF CONTENTS ARTICLE I DEFINITIONS 4 ARTICLE II PURCHASE AND SALE 6 Section 2.
October 25, 2024	S-3	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 Registration Statement Under THE SECURITIES ACT OF 1933 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including zip code, and telephone number i
October 25, 2024	EX-FILING FEES	Calculation of Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables S-3 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock, Preferred Stock, Rights and Warrants Rule 457(o) 1,000,000 $ 0.
October 11, 2024	POS AM	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 POST-EFFECTIVE AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 Registration No 333-265995 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 POST-EFFECTIVE AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-09l6344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Nu
October 11, 2024	EX-FILING FEES	Calculation of Filing Fee Tables Post-Effective Amendment No. 1 (Form Type) Cel-Sci Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities EXHIBIT 107 Calculation of Filing Fee Tables S-3 Post-Effective Amendment No. 1 (Form Type) Cel-Sci Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amou
October 10, 2024	AW	CEL-SCI CORPORATION 8229 Boone Blvd. #802 Vienna, VA 22182 (703) 506-9460 October 10, 2024 CEL-SCI CORPORATION 8229 Boone Blvd. #802 Vienna, VA 22182 (703) 506-9460 October 10, 2024 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Amendment to Registration Statement on Form S-3 File No. 333-265995 CEL-SCI Corporation (the “Company”) requests that the above-captioned Amendment to its registration statement on Form S-3 filed on October 8, 2024 (File No. 333-265
October 8, 2024	EX-FILING FEES	Calculation of Filing Fee Tables Post-Effective Amendment No. 1 (Form Type) Cel-Sci Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities EXHIBIT 107 Calculation of Filing Fee Tables S-3 Post-Effective Amendment No. 1 (Form Type) Cel-Sci Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amou
October 8, 2024	S-3/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 POST-EFFECTIVE AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 Registration No 333-265995 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 POST-EFFECTIVE AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-09l6344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Nu
September 17, 2024	EX-99	CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation EXHIBIT 99 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation · 5-year survival rate of 82.6% and
September 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 16, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 16, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission
August 30, 2024	S-8	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of l933 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of l933 CEL-SCI CORPORATION (Exact name of issuer as specified in its charter) Colorado 84-0916344 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8229 Boone Blvd., Suite 802 Vienna, Virginia 22182 (Address of Principal Executive Off
August 30, 2024	EX-99	Additional Exhibits EXHIBIT 99 CEL-SCI CORPORATION Common Stock This Prospectus relates to shares (the "Shares") of common stock (the "Common Stock") of CEL-SCI Corporation which may be issued pursuant to certain employee compensation plans adopted by CEL-SCI.
August 30, 2024	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables S-8 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock, Preferred Stock, Rights and Warrants Rule 457(o) 2,000,000 $ 1.
August 30, 2024	EX-4.B	Non-Qualified Stock Option Plan EXHIBIT 4(b) CEL-SCI CORPORATION 2024 NON-QUALIFIED STOCK OPTION PLAN l. Purpose. This Non-Qualified Stock Option Plan (the "Plan") is intended to advance the interests of CEL-SCI Corporation (the “Company”) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for th
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SCI
July 29, 2024	424B5	Per Share Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) 3,715,000 Shares of Common Stock 7,130,000 Pre-Funded Warrants to Purchase Shares of Common Stock 7,130,000 Shares of Common Stock underlying the Pre-Funded Warrants CEL-SCI Corporation We are offering 3,715,000 shares of our common stock, par value $0.01 per share, at an offering
July 29, 2024	EX-99.1	Gavin de Windt EXHIBIT 99.1 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $10.8 MILLION OFFERING Vienna, Virginia – July 26, 2024 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a cancer immunotherapy company, today announced the pricing of a be
July 29, 2024	EX-99.2	CEL-SCI ANNOUNCES CLOSING OF $10.8 MILLION OFFERING EXHIBIT 99.2 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF $10.8 MILLION OFFERING Vienna, Virginia – July 29, 2024 — CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a cancer immunotherapy company, today announced the closing of its
July 29, 2024	EX-1.1	Placement Agency Agreement dated July 26. 2024, by and between CEL-SCI Corporation and ThinkEquity, LLC EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC 1 CEL-SCI CORPORATION PLACEMENT AGENCY AGREEMENT New York, New York July 26, 2024 ThinkEquity LLC 17 State Street, 41st Floor New York, NY 10004 Ladies and Gentlemen: This Placement Agency Agreement (the "Agreement") sets forth the terms upon which ThinkEquity LLC ("ThinkEquity" or the "Placement Agent") shall b
July 29, 2024	EX-4.1	Form of Pre-Funded Warrant EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT CEL-SCI CORPORATION Warrant Shares: Issue Date: June, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and unti
July 29, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 26, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 26, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File
July 26, 2024	EX-99	3 EXHIBIT 99 NEWS 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI’S PHASE 3 POPULATION ANALYSIS FOR UPCOMING CONFIRMATORY REGISTRATION STUDY IN HEAD & NECK CANCER DEMONSTRATES WELL BALANCED PATIENT POPULATION, CONFIDENCE IN CLINICAL RESULTS · Multikine, a true first-line cancer i
July 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 26, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 26, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File
June 20, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 18, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction (Commission (IRS Employer of incorp
June 20, 2024	EX-99	CEL-SCI PRESENTS HEAD & NECK CANCER DATA AT IDDST ANNUAL CONGRESS IN BUDAPEST: RISK OF DEATH CUT IN HALF FOR PATIENTS TREATED WITH MULTIKINE IN THE TARGET POPULATION EXHIBIT 99 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI PRESENTS HEAD & NECK CANCER DATA AT IDDST ANNUAL CONGRESS IN BUDAPEST: RISK OF DEATH CUT IN HALF FOR PATIENTS TREATED WITH MULTIKINE IN THE TARGET POPULATION · Multikine significantly increases overall survival in patie
May 15, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SC
April 23, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 19, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File
April 19, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 19, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 19, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File
March 7, 2024	ARS	ARS
March 7, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive
March 7, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☒ Definitive
March 7, 2024	ARS	ARS - PDF COPY Annual Report 2023 2 CEL-SCI’s Corporation CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system.
February 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL
February 13, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 8, 2024 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission Fi
February 13, 2024	EX-99.2	CEL-SCI ANNOUNCES CLOSING OF $7.75 MILLION PUBLIC OFFERING OF COMMON STOCK EXHIBIT 99.2 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF $7.75 MILLION PUBLIC OFFERING OF COMMON STOCK Vienna, VA, February 13, 2024 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today a
February 13, 2024	EX-1.1	Underwriting Agreement dated as of February 8, 2024, by and between CEL-SCI Corporation and ThinkEquity, LLC EXHIBIT 1.1 Execution Version UNDERWRITING AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC as Representative of the Several Underwriters 1 CEL-SCI CORPORATION UNDERWRITING AGREEMENT New York, New York February 8, 2024 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Floor New York, NY 10004 Ladies and Gentlemen: The u
February 13, 2024	EX-99.1	CEL-SCI ANNOUNCES PRICING OF $7.75 MILLION PUBLIC OFFERING OF COMMON STOCK EXHIBIT 99.1 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $7.75 MILLION PUBLIC OFFERING OF COMMON STOCK Vienna, VA, February 9, 2024 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today an
February 9, 2024	424B5	Per Share Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) 3,875,000 Shares Common Stock CEL-SCI Corporation We are offering 3,875,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price equal to $2.00 per share. Our common stock is listed on the N
December 22, 2023	EX-4.B	2023 Non-Qualified Stock Option Plan EXHIBIT 4(b) CEL-SCI CORPORATION 2023 NON-QUALIFIED STOCK OPTION PLAN l. Purpose. This Non-Qualified Stock Option Plan (the "Plan") is intended to advance the interests of CEL-SCI Corporation (the “Company”) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for th
December 22, 2023	EX-4.C	Stock Bonus Plan EXHIBIT 4(c) CEL-SCI CORPORATION 2023 STOCK BONUS PLAN l. Purpose. The purpose of this Stock Bonus Plan is to advance the interests of CEL-SCI Corporation (the “Company”) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for the successful conduct of its business,
December 22, 2023	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables S-8 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock, Preferred Stock, Rights and Warrants Rule 457(o) 2,500,000 $ 2.
December 22, 2023	EX-99	Additional Exhibits EXHIBIT 99 CEL-SCI CORPORATION Common Stock This Prospectus relates to shares (the "Shares") of common stock (the "Common Stock") of CEL-SCI Corporation which may be issued pursuant to certain employee compensation plans adopted by CEL-SCI.
December 22, 2023	S-8	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of l933 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of l933 CEL-SCI CORPORATION (Exact name of issuer as specified in its charter) Colorado 84-0916344 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8229 Boone Blvd., Suite 802 Vienna, Virginia 22182 (Address of Principal Executive Off
December 21, 2023	10-K	FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-11889 CEL-SCI CORPORATION (Exact
December 21, 2023	EX-97	Policy relating to Recovery of Erroneously Awarded Compensation EXHIBIT 97 CEL-SCI CORPORATION Compensation Recovery Policy 1 TABLE OF CONTENTS Overview 3 Section 1.
November 20, 2023	EX-99.1	CEL-SCI ANNOUNCES PRICING OF $5 MILLION OFFERING OF COMMON STOCK EXHIBIT 99.1 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $5 MILLION OFFERING OF COMMON STOCK Vienna, VA, November 16, 2023 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced t
November 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 15, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 15, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission F
November 20, 2023	EX-99.2	CEL-SCI ANNOUNCES CLOSING OF $5 MILLION PUBLIC OFFERING OF COMMON STOCK EXHIBIT 99.2 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF $5 MILLION PUBLIC OFFERING OF COMMON STOCK Vienna, VA, November 20, 2023 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today anno
November 20, 2023	EX-1.1	Underwriting Agreement dated as of November 15, 2023, by and between CEL-SCI Corporation and ThinkEquity, LLC EXHIBIT 1.1 UNDERWRITING AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC as Representative of the Several Underwriters 1 CEL-SCI CORPORATION UNDERWRITING AGREEMENT New York, New York November 15, 2023 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Floor New York, NY 10004 Ladies and Gentlemen: The undersigned, CEL-S
November 16, 2023	424B5	Per Share Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) 2,490,000 Shares Common Stock CEL-SCI Corporation We are offering 2,490,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price equal to $2.00 per share. Our common stock is listed on the N
October 30, 2023	EX-10.10	Extension of Employment Agreement with Geert Kersten (2023-2027) EXHIBIT 10.10 EXTENSION OF EMPLOYMENT AGREEMENT The parties hereby agree that the term of the Employment Agreement made by and between Geert Kersten and CEL-SCI Corporation as of August 31, 2019 is extended to August 31, 2027. All other terms of the Employment Agreement with Mr. Kersten dated August 31, 2019 remain the same. October 26, 2023 CEL-SCI CORPORATION By: /s/ Patricia Prichep Patricia B.
October 30, 2023	EX-99.1	CEL-SCI Issues Letter to Shareholders View the letter: https://cel-sci.com/wp-content/uploads/2023/10/CEL-SCI_shareholder_letter_from_CEO_Oct2023.pdf EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com NYSE American: CVM COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI Issues Letter to Shareholders View the letter: https://cel-sci.com/wp-content/uploads/2023/10/CEL-SCIshareholderletterfromCEOOct2023.pdf Vienna, VA: October 30, 2023 — CEL-SCI Corporati
October 30, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 26, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission Fi
October 24, 2023	EX-99	8229 Boone Boulevard, Suite 802 EXHIBIT 99 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com NYSE American: CVM COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023 ➢ Target patient po
October 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 23, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 23, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission Fi
August 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 28, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 28, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) ( Commission Fi
August 31, 2023	EX-10.10	Extension of Employment Agreement with Patricia Prichep (2023-2027) EXHIBIT 10.10 EXTENSION OF EMPLOYMENT AGREEMENT The parties hereby agree that the term of the Employment Agreement made by and between Patricia B. Prichep and CEL-SCI Corporation as of August 31, 2019 is extended to August 31, 2027. All other terms of the Employment Agreement with Ms. Prichep dated August 31, 2019 remain the same. August 28, 2023 CEL-SCI CORPORATION By: /s/ Geert Kersten Geert R.
August 31, 2023	EX-10.11	Extension of Employment Agreement with Eyal Talor (2023-2027) EXHIBIT 10.11 EXTENSION OF EMPLOYMENT AGREEMENT The parties hereby agree that the term of the Employment Agreement made by and between Eyal Talor and CEL-SCI Corporation as of August 31, 2019 is extended to August 31, 2027. All other terms of the Employment Agreement with Dr. Talor dated August 31, 2019 remain the same. August 28, 2023 CEL-SCI CORPORATION By: /s/Geert Kersten Geert R. Kersten, Chi
August 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SCI
July 20, 2023	EX-99	CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING EXHIBIT 99 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING Vienna, VA, July 20, 2023 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of its previous
July 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 20, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 20, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File
July 18, 2023	424B5	Per Share Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) 2,500,000 Shares Common Stock CEL-SCI Corporation We are offering 2,500,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus, at an offering price of $2.00 per share. Our common stock is listed on the NYSE American under the symbol
July 18, 2023	EX-1.1	Underwriting Agreement dated as of July 17, 2023, by and between CEL-SCI Corporation and ThinkEquity, LLC, as a Representative of the Several Underwriters EXHIBIT 1.1 UNDERWRITING AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC as Representative of the Several Underwriters 1 CEL-SCI CORPORATION UNDERWRITING AGREEMENT New York, New York July 17, 2023 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Floor New York, New York 10004 Ladies and Gentlemen: The undersigned, CEL
July 18, 2023	EX-99.1	CEL-SCI ANNOUNCES PRICING OF PUBLIC OFFERING EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF PUBLIC OFFERING Vienna, VA, July 17, 2023 – CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing
July 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 17, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 17, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File
July 17, 2023	FWP	FWP
July 17, 2023	424B5	SUBJECT TO COMPLETION Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended. This preliminary prospectus su
July 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 14, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 14, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File
July 14, 2023	EX-99	Gavin de Windt CEL-SCI Corporation (703) 506-9460 EXHIBIT 99 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI CONCLUDES POSITIVE MEETING WITH U.S. FDA CONCERNING MULTIKINE’S APPROVAL FOR HEAD & NECK CANCER · FDA acknowledges the great need for improved treatments for head and neck cancer, particularly the locally a
July 12, 2023	EX-99	CEL-SCI REPORTS PHASE 3 TUMOR PD-L1 BIOMARKER DATA DEMONSTRATE MULTIKINE’S INCREASED EFFICACY AND POINTS TO POTENTIAL FOR COMBINATION WITH CHECKPOINT INHIBITORS FOR HEAD & NECK CANCER EXHIBIT 99 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI REPORTS PHASE 3 TUMOR PD-L1 BIOMARKER DATA DEMONSTRATE MULTIKINE’S INCREASED EFFICACY AND POINTS TO POTENTIAL FOR COMBINATION WITH CHECKPOINT INHIBITORS FOR HEAD & NECK CANCER · Multikine significantly increases overall
July 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 11, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 11, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction (Commission File No.) (IRS Employer
May 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 23, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 23, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File N
May 12, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SC
May 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 2, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 2, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File No
May 1, 2023	EX-99.1	CEL-SCI ANNOUNCES $1.35 MILLION UNDERWRITTEN CONFIDENTIALLY MARKETED PUBLIC OFFERING OF COMMON STOCK EXHIBIT 99.1 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES $1.35 MILLION UNDERWRITTEN CONFIDENTIALLY MARKETED PUBLIC OFFERING OF COMMON STOCK Vienna, VA, April 27, 2023 - CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunot
May 1, 2023	424B5	CEL-SCI CORPORATION 794,117 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-265995 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 15, 2022) CEL-SCI CORPORATION 794,117 Shares of Common Stock We are offering 794,117 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price equal to $1.70 per share. Our common stock is listed on the NY
May 1, 2023	EX-1.1	Underwriting Agreement dated as of April 27, 2023, by and between CEL-SCI Corporation and Spartan Capital Securities, LLC, as a Representative of the Several Underwriters EX-1.1 2 cvmex11.htm UNDERWRITING AGREEMENT DATED EXHIBIT 1.1 UNDERWRITING AGREEMENT between CEL-SCI CORPORATION and SPARTAN CAPITAL SECURITIES, LLC as Representative of the Several Underwriters -1- CEL-SCI Corporation 8229 Boone Blvd. #802 Vienna, Virginia 22182 UNDERWRITING AGREEMENT New York, New York April 27, 2023 Spartan Capital Securities, LLC As Representative of the several Underwriters n
May 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 27, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 27, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File
April 19, 2023	EX-99	CEL-SCI TO PURSUE CANADA’S CONDITIONAL APPROVAL PATHWAY FOR MULTIKINE IN THE TREATMENT OF HEAD & NECK CANCER EXHIBIT 99 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI TO PURSUE CANADA’S CONDITIONAL APPROVAL PATHWAY FOR MULTIKINE IN THE TREATMENT OF HEAD & NECK CANCER · Follows pre-submission meeting with Canada’s regulator Health Canada · Plans to pursue marketing approv
April 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 19, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 19, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction (Commission File No.) (IRS Employe
April 10, 2023	ARS	ARS
April 10, 2023	ARS	ARS - COMPLIMENTARY PDF Annual Report 2022 2 CEL-SCI Corporation CEL-SCI is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system.
April 10, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☒ Definitive
April 10, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive
March 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 8, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 8, 2023 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File
March 9, 2023	EX-99	CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension EXHIBIT 99 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension · Presented at the 10th European Congress on Head & Neck Oncology · Six Different Efficacy Measures Demonstrate Benefits of Adding Multikine to Standard of C
February 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL
December 27, 2022	10-K	FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-11889 CEL-SCI CORPORATION (Exact
September 13, 2022	EX-99	8229 Boone Boulevard, Suite 802 EXHIBIT 99 NEWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182.
September 13, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 12, 2022 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission
August 22, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 19, 2022 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction (Commission (IRS Employer of inco
August 22, 2022	EX-99.1	CEL-SCI CORPORATION ANNOUNCES PHASE 3 MULTIKINE® HEAD AND NECK CANCER RESULTS POSTED ON CLINICALTRIALS.GOV EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com CEL-SCI CORPORATION ANNOUNCES PHASE 3 MULTIKINE® HEAD AND NECK CANCER RESULTS POSTED ON CLINICALTRIALS.GOV The “Proposed Indication” for Multikine that will be submitted to the FDA in a license application will be limited by certain eligibility criteria to patients who would be
August 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SCI
August 8, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 2, 2022 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File
July 1, 2022	S-3	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 Registration Statement Under THE SECURITIES ACT OF 1933 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-09l6344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including zip code, and telephone number i
July 1, 2022	EX-FILING FEES	EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Tables S-8 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock, Preferred Stock, Rights and Warrants Rule 457(o) 3,800,000 $ 3.
July 1, 2022	S-8	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of l933 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of l933 CEL-SCI CORPORATION (Exact name of issuer as specified in its charter) Colorado 84-0916344 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8229 Boone Blvd., Suite 802 Vienna, Virginia 22182 (Address of Principal Executive Off
July 1, 2022	EX-4.B	Non-Qualified Stock Option Plan EXHIBT 4(b) CEL-SCI CORPORATION 2022 NON-QUALIFIED STOCK OPTION PLAN l. Purpose. This Non-Qualified Stock Option Plan (the ?Plan?) is intended to advance the interests of CEL-SCI Corporation (the ?Company?) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for the
July 1, 2022	EX-FILING FEES	Filling Fee Table EXHIBIT 107 Calculation of Filing Fee Tables S-3 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock, Preferred Stock, Rights and Warrants Rule 457(o) $ 150,000,000 $92.
July 1, 2022	EX-99	EX-99 EX-99 6 cvmex99.htm CEL-SCI CORPORATION EXHIBIT 99 CEL-SCI CORPORATION Common Stock THESE SECURITIES INVOLVE A HIGH DEGREE OF RISK. SEE “RISK FACTORS”. THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION, NOR HAS THE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS.
July 1, 2022	POS AM	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 POST-EFFECTIVE AMENDMENT NO. 5 Registration Statement Under THE SECURITIES ACT OF 1933 File # 333-229295 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 POST-EFFECTIVE AMENDMENT NO. 5 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 2836 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number
July 1, 2022	EX-FILING FEES.107	Filling Fee Table EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) CEL-SCI Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Equity Common Stock Rule 457(c) 1,079,483 $ 3.
June 13, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 13, 2022 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File
May 13, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SC
April 29, 2022	ARS	ARS ARS 1 cvmars.htm ARS
April 29, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive
April 29, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ? Definitive
April 29, 2022	ARS	ARS - COMPLIMENTARY PDF
February 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL
December 21, 2021	10-K	FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-11889 CEL-SCI CORPORATION (Exact
August 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SCI
July 7, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 7, 2021 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File N
July 7, 2021	EX-99	CEL-SCI CORPORATION ISSUES LETTER TO SHAREHOLDERS EXHIBIT 99 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI CORPORATION ISSUES LETTER TO SHAREHOLDERS Vienna, VA, July 7, 2021 - CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders. Dear CEL-SCI shareholders: The purpose of this letter
July 2, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 1, 2021 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File N
June 29, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 28, 2021 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File
June 9, 2021	EX-99.1	CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING EXHIBIT 99.1 NEWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING Vienna, VA, June 8, 2021 - CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it has entered into an underwriting agreeme
June 9, 2021	424B5	(Subject to Completion, dated June 8, 2021) Filed pursuant to Rule 424(b)(5) Registration No. 333-226558 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, but the information in this prospectus supplement is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell the securities and
June 9, 2021	EX-1.1	EX-1.1 Exhibit 1.1 AMENDED and RESTATED UNDERWRITING AGREEMENT between CEL-SCI Corporation and KINGSWOOD CAPITAL MARKETS, division of Benchmark Investments, LLC, as Representative of the Several Underwriters 1 CEL-SCI CORPORATION UNDERWRITING AGREEMENT New York, New York June 8, 2021 Kingswood Capital Markets, division of Benchmark Investments, LLC As Representative of the several Underwriters named on S
June 9, 2021	EX-99.2	CEL-SCI INCREASES PREVIOUSLY ANNOUNCED BOUGHT DEAL TO $31.7 MILLION EXHIBIT 99.2 NEWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI INCREASES PREVIOUSLY ANNOUNCED BOUGHT DEAL TO $31.7 MILLION Vienna, VA, June 8, 2021 - CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that, due to demand
June 9, 2021	8-K	Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 8, 2021 CEL SCI CORP (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File No.) (IR
June 9, 2021	FWP	TERM SHEET CEL-SCI CORPORATION Public Offering of Common Stock Filed pursuant to Rule 433 Registration Statement No.: 333-226558 Issuer Free Writing Prospectus dated June 8, 2021 Relating to Preliminary Prospectus Supplement dated June 8, 2021 TERM SHEET CEL-SCI CORPORATION Public Offering of Common Stock This document does not provide full disclosure of all material facts relating to the securities offered. Investors should read the accompanying prospectus,
June 9, 2021	424B5	CEL-SCI CORPORATION 1,400,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-226558 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 24, 2018) CEL-SCI CORPORATION 1,400,000 Shares of Common Stock We are offering 1,400,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price equal to $22.62 per share. Our common stock is listed on
May 18, 2021	ARS	ARS ARS 1 cvmars.htm ARS
May 18, 2021	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ? Definitive
May 18, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive
May 17, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SC
February 12, 2021	10-Q	Quarterly Report - QUARTELRY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL
January 15, 2021	POS AM	- AMENDMENT NO 4 POS AM 1 cvmposam.htm AMENDMENT NO 4 File # 333-229295 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 POST-EFFECTIVE AMENDMENT NO. 4 Registration Statement Under THE SECURITIES ACT OF 1933 Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including zip code, and tel
December 31, 2020	10-Q/A	Quarterly Report - JUNE 30, 2020 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 2) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Numb
December 30, 2020	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num
December 30, 2020	10-Q/A	Quarterly Report - DECEMBER 31, 2019 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File
December 29, 2020	8-K	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 23, 2020 CEL SCI CORP (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File No.
December 29, 2020	10-K	Annual Report - 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-11889 CEL-SCI CORPORATION (Exac
December 9, 2020	EX-1.1	EX-1.1 EXHIBIT 1.1 UNDERWRITING AGREEMENT between CEL-SCI Corporation and KINGSWOOD CAPITAL MARKETS, division of Benchmark Investments, Inc., as Representative of the Several Underwriters 1 CEL-SCI CORPORATION UNDERWRITING AGREEMENT New York, New York December 8, 2020 Kingswood Capital Markets, division of Benchmark Investments, Inc. As Representative of the several Underwriters named on Schedule 1 attac
December 9, 2020	8-K	Entry into a Material Definitive Agreement, Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 8, 2020 CEL SCI CORP (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File No.)
December 9, 2020	EX-99.1	CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING EXHIBIT 99 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING Vienna, VA, December 8, 2020 - CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it has entered into an underwriting agree
December 9, 2020	424B5	CEL-SCI CORPORATION 1,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-226558 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 24, 2018) CEL-SCI CORPORATION 1,000,000 Shares of Common Stock We are offering 1,000,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price equal to $14.65 per share. Our common stock is listed on
December 9, 2020	FWP	Issuer General Use Free Writing Prospectus Issuer General Use Free Writing Prospectus Filed pursuant to Rule 433 Registration Statement No.
December 9, 2020	424B5	(Subject to Completion, dated December 8, 2020) Filed pursuant to Rule 424(b)(5) Registration No. 333-226558 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, but the information in this prospectus supplement is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell the securities and
December 7, 2020	8-K	Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 7, 2020 CEL SCI CORP (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File No.)
December 7, 2020	EX-99.1	CEL-SCI Announces Update on Phase 3 Cancer Trial Results Data lock is complete, final statistical analysis being conducted EXHIBIT 99 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI Announces Update on Phase 3 Cancer Trial Results Data lock is complete, final statistical analysis being conducted Vienna, VA, December 7, 2020 - CEL-SCI Corporation (NYSE American: CVM) announced today tha
October 30, 2020	8-K	Material Modification to Rights of Security Holders - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 30, 2020 CEL SCI CORP (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File No.)
October 30, 2020	EX-4	Shareholders Rights Agreement, as Amended EX-4 2 cvmex4.htm SHAREHOLDER RIGHTS AGREEMENT Exhibit 4 SHAREHOLDER RIGHTS AGREEMENT (As Amended) CEL-SCI CORPORATION 8229 Boone Boulevard, Suite 802 Vienna, Virginia 22182 TABLE OF CONTENTS SECTION PAGE Section 1. Certain Definitions 2 Section 2. Appointment of Rights Agent 6 Section 3. Issue of Right Certificates 6 Section 4. Form of Right Certificates 8 Section 5. Countersignature and Registra
August 11, 2020	10-Q/A	Quarterly Report - AMENDED QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No.1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Numbe
August 10, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SCI
July 2, 2020	S-1	Registration Statement - REGISTRATION STATEMENT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including zip code, and telephone number i
July 2, 2020	EX-10.11	EX-10.11 EX-10.11 4 cvmex1011.htm SECURITIES PURCHASE AGREEMENT WITH ERGOMED EXHIBIT 10.11 SECURITIES PURCHASE AGREEMENT between CEL-SCI CORPORATION and ERGOMED plc dated as of June 29, 2020 1 TABLE OF CONTENTS ARTICLE I DEFINITIONS 3 ARTICLE II PURCHASE AND SALE 5 Section 2.01 Purchase and Sale. 5 Section 2.02 Transactions Effected at the Closing. 5 Section 2.03 Closing. 6 ARTICLE III REPRESENTATIONS AND
July 2, 2020	EX-10.10	EX-10.10 Exhibit 10.10 May 27, 2020 CONFIDENTIAL Mr. Geert R. Kersten Director and Chief Executive Officer CEL-SCI Corporation 8229 Boone Boulevard, Suite 802 Vienna, Virginia 22182 Re: Warrant Solicitation Engagement Dear Geert: The purpose of this engagement letter (the “Warrant Solicitation Agreement” or “Agreement”)) is to set forth our agreement pursuant to which Dawson James Securities, Inc. (“Dawson
July 1, 2020	8-K	Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 25, 2020 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 01-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File N
May 26, 2020	8-K	Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 26, 2020 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File N
May 26, 2020	EX-4.(F)	EX-4.(F) Exhibit 4(f) COMMON STOCK PURCHASE WARRANT SERIES YY CEL-SCI CORPORATION Warrant Shares: Issuance Date: June 26, 2020 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the “Initial Exercise Date” and on or prior to the close of business on the “Termination Date” but not thereafter, to subscribe for and purchase from CEL-SCI Corporation, a Colorado corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock.
May 26, 2020	EX-4.(G)	EX-4.(G) Exhibit 4(g) COMMON STOCK PURCHASE WARRANT SERIES XX CEL-SCI CORPORATION Warrant Shares: Issuance Date: June 11, 2020 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the “Initial Exercise Date” and on or prior to the close of business on the “Termination Date” but not thereafter, to subscribe for and purchase from CEL-SCI Corporation, a Colorado corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock.
May 26, 2020	424B3	CEL-SCI CORPORATION Series V Warrants PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(3) (To Prospectus Supplement Registration No.
May 8, 2020	10-Q	Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL-SC
April 24, 2020	EX-4.B	(b) - 2020 Non-Qualified Stock Option Plan Exhibit 4(b) CEL-SCI CORPORATION 2020 NON-QUALIFIED STOCK OPTION PLAN l. Purpose. This Non-Qualified Stock Option Plan (the "Plan") is intended to advance the interests of CEL-SCI Corporation (the “Company”) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for th
April 24, 2020	S-8	- REGISTRATION STATEMENT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of l933 CEL-SCI CORPORATION (Exact name of issuer as specified in its charter) Colorado 84-0916344 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8229 Boone Blvd., Suite 802 Vienna, Virginia 22182 (Address of Principal Executive Off
April 24, 2020	EX-99	99 - Additional Exhibits (Re-Offer Prospectus) Exhibit 99 CEL-SCI CORPORATION Common Stock THESE SECURITIES INVOLVE A HIGH DEGREE OF RISK.
April 17, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 17, 2020 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File
April 15, 2020	CORRESP	- CEL-SCI CORPORATION 8229 Boone Blvd. #802 Vienna, VA 22182 (703) 506-9460 April 15, 2020 Irene Paik Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: CEL-SCI Corporation Form S-1 SEC File No. 333-327623 CEL-SCI Corporation (the “Company”) requests that the effective date of the above captioned Registration Statement be accelerated to Monday, April 20, 2020 at 2:00 P.M. E
April 9, 2020	EX-10.9	EX-10.9 Exhibit 10.9
April 9, 2020	S-1	CVM / CEL-SCI Corp. S-1 - Registration Statement - REGISTRATION STATEMENT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including zip code, and telephone number i
March 30, 2020	DEFA14A	CVM / CEL-SCI Corp. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive
March 24, 2020	EX-99.2	CEL-SCI INCREASES PREVIOUSLY ANNOUNCED BOUGHT DEAL TO $7.7 MILLION EXHIBIT 99.2 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI INCREASES PREVIOUSLY ANNOUNCED BOUGHT DEAL TO $7.7 MILLION Vienna, VA, March 24, 2020 - CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, announced today that, due to demand, the underw
March 24, 2020	424B5	CEL-SCI CORPORATION 630,500 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-226558 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 24, 2018) CEL-SCI CORPORATION 630,500 Shares of Common Stock We are offering 630,500 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price equal to $12.22 per share. Our common stock is listed on the
March 24, 2020	EX-99.1	CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING EXHIBIT 99.1 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING Vienna, VA, March 23, 2020 - CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced today that it has entered into an underwriting agreement wi
March 24, 2020	FWP	Issuer General Use Free Writing Prospectuses Issuer General Use Free Writing Prospectuses Filed pursuant to Rule 433 Registration Statement No.
March 24, 2020	424B5	(Subject to Completion, dated March 23, 2020) Filed pursuant to Rule 424(b)(5) Registration No. 333-226558 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, but the information in this prospectus supplement is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell the securities and
March 24, 2020	FWP	Issuer General Use Free Writing Prospectuses Issuer General Use Free Writing Prospectuses Filed pursuant to Rule 433 Registration Statement No.
March 24, 2020	8-K	Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 23, 2020 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission File
March 24, 2020	EX-1.1	EX-1.1 EXHIBIT 1 AMENDED AND RESTATED UNDERWRITING AGREEMENT between CEL-SCI Corporation and AEGIS CAPITAL CORP.
March 17, 2020	DEFA14A	CVM / CEL-SCI Corp. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive
March 13, 2020	POS AM	CVM / CEL-SCI Corp. POS AM - - POS AM File # 333-229295 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 POST-EFFECTIVE AMENDMENT NO. 3 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Ad
March 13, 2020	EX-3.D	Bylaws (as amended) Exhibit 3(d) BYLAWS OF CEL-SCI CORPORATION ARTICLE I OFFICES Section l. Offices: The principal office of the Corporation shall be determined by the Board of Directors, and the Corporation shall have other offices at such places as the Board of Directors may from time to time determine. ARTICLE II STOCKHOLDER'S MEETINGS Section l. Place: The place of stockholders' meetings shall be the principal of
March 6, 2020	POS AM	CVM / CEL-SCI Corp. POS AM - - POS AM File # 333-229295 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 POST-EFFECTIVE AMENDMENT NO. 2 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Ad
March 4, 2020	ARS	ARS
March 4, 2020	DEFA14A	CVM / CEL-SCI Corp. DEFA14A - - DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive
March 4, 2020	DEF 14A	CVM / CEL-SCI Corp. DEF 14A - - DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☒ Definitive
March 4, 2020	ARS	ARS
February 21, 2020	POS AM	CVM / CEL-SCI Corp. POS AM - - POS AM File # 333-229295 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 POST-EFFECTIVE AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Ad
February 20, 2020	S-1/A	CVM / CEL-SCI Corp. S-1/A - - S-1/A File # 333-229295 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 POST-EFFECTIVE AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Ad
February 10, 2020	10-Q	CVM / CEL-SCI Corp. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-11889 CEL
February 3, 2020	POS AM	CVM / CEL-SCI Corp. POS AM - - POS AM SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 POST-EFFECTIVE AMENDMENT NO. 1 Registration Statement Under THE SECURITIES ACT OF 1933 CEL-SCI CORPORATION (Exact name of registrant as specified in charter) Colorado (State or other jurisdiction of incorporation) 84-0916344 8229 Boone Blvd. #802 Vienna, Virginia 22182 (703) 506-9460 (IRS Employer I.D. Number) (Address, including z
January 24, 2020	S-8	CVM / CEL-SCI Corp. S-8 - - REGISTRATION STATEMENT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of l933 CEL-SCI CORPORATION (Exact name of issuer as specified in its charter) Colorado 84-0916344 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 8229 Boone Blvd., Suite 802 Vienna, Virginia 22182 (Address of Principal Executive Off
January 24, 2020	EX-99	Additional Exhibits (Re-Offer Prospectus) EXHIBIT 99 CEL-SCI CORPORATION Common Stock THESE SECURITIES INVOLVE A HIGH DEGREE OF RISK.
January 24, 2020	EX-4.C	Stock Compensation Plan EXHIBIT 4(c) CEL-SCI CORPORATION 2019 STOCK COMPENSATION PLAN CEL-SCI Corporation (“the Company”) hereby adopts this Stock Compensation Plan.
January 24, 2020	EX-4.B	(b) - 2019 Non-Qualified Stock Option Plan EXHIBIT 4(b) CEL-SCI CORPORATION 2019 NON-QUALIFIED STOCK OPTION PLAN l. Purpose. This Non-Qualified Stock Option Plan (the "Plan") is intended to advance the interests of CEL-SCI Corporation (the “Company”) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for th
December 26, 2019	424B5	CEL-SCI CORPORATION Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-226558 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 24, 2018) CEL-SCI CORPORATION Shares of Common Stock We are offering 606,395 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price equal to $9.07 per share of common stock. Our common stock is listed
December 26, 2019	EX-1.1	EX-1.1 EXHIBIT 1.1 UNDERWRITING AGREEMENT between CEL-SCI Corporation and AEGIS CAPITAL CORP., as Representative of the Several Underwriters CEL-SCI CORPORATION UNDERWRITING AGREEMENT New York, New York December 23, 2019 Aegis Capital Corp. As Representative of the several Underwriters named on Schedule 1 attached hereto 810 Seventh Avenue, 18th Floor New York, New York 10019 Ladies and Gentlemen: The un
December 26, 2019	8-K	Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 23, 2019 CEL-SCI CORPORATION (Exact name of Registrant as specified in its charter) Colorado 001-11889 84-0916344 (State or other jurisdiction of incorporation) (Commission F
December 26, 2019	EX-99.1	CEL-SCI PRICES $5.5 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK EXHIBIT 99.1 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI PRICES $5.5 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK Vienna, VA, December 24, 2019 - CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of an unde
December 23, 2019	424B5	(Subject to Completion, dated December 23, 2019) Filed pursuant to Rule 424(b)(5) Registration No. 333-226558 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, but the information in this prospectus supplement is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell the securities and
December 23, 2019	10-K/A	CVM / CEL-SCI Corp. 10-K/A - Annual Report - FORM 10-K/A FORM 10-K/A (Amendment No.1) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) (X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2019. OR ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-11889 CEL-

CVM / CEL-SCI Corporation - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings